ATNM - Actinium Pharmaceuticals, Inc.
| Previous Close | 0.4300 |
| Open | 0.4700 |
| Bid | 0.3699 x 1400 |
| Ask | 0.6984 x 1000 |
| Day's Range | 0.4175 - 0.4500 |
| 52 Week Range | 0.3320 - 0.8650 |
| Volume | 513,704 |
| Avg. Volume | 1,055,003 |
| Market Cap | 48.327M |
| Beta (3Y Monthly) | 2.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2310 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.29 |
- PR Newswire•11 days ago
Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
- Key highlights include near universal engraftment and no 100-day non-relapse mortality in patients randomized to Iomab-B arm; 79% of patients in the control arm failed to achieve a complete response ...
- PR Newswire•12 days ago
Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate
- Phase 2 trial successfully reached predetermined response criteria in difficult to treat over 60, unfit patient population and demonstrated minimal extramedullary toxicities - Actinium's CD33 program ...
- PR Newswire•26 days ago
Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
- Actinium presentation scheduled for November 27 at 2:10pm EST NEW YORK , Nov. 19, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that management will present ...
- PR Newswire•last month
Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference
- Presentation at 9:00 AM CET on Tuesday, November 6, 2018 - Actinium to highlight its highly differentiated targeted conditioning Antibody Radiation Conjugates including Pivotal Phase 3 Program Iomab-B, ...
- PR Newswire•last month
Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data
NEW YORK, Nov. 1, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that multiple abstracts highlighting its Antibody Radiation Conjugates (ARCs) have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, including an oral presentation of preliminary feasibility and safety results from its pivotal Phase 3 SIERRA trial of Iomab-B. The ASH Annual Meeting is being held December 1 – 4, 2018 in San Diego, California. Data presented will highlight Actinium's lead product candidate, Iomab-B, that is intended to be a targeted conditioning agent prior to a bone marrow transplant for patients with active relapsed or refractory Acute Myeloid Leukemia (AML) who are over the age of 55.
- PR Newswire•2 months ago
Actinium Pharmaceuticals CD33 Program to Focus on Actimab-MDS Pivotal Trial Enabling Study for Targeted Conditioning and Novel Combination Trials with Actimab-A and Venetoclax
- Positive FDA discussions for Actimab-MDS program enable accelerated pivotal trial pathway and broaden target patient population - Actimab-A development strategy in combinations with Venetoclax for AML ...
- PR Newswire•2 months ago
Actinium Pharmaceuticals to Hold Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update
-Conference call and webcast today at 11:00 AM ET -Dr. Gary Schiller, Professor of Medicine, Director, Hematologic Malignancy/Stem Cell Transplant Program at UCLA Medical Center and Dr. Tapan Kadia, Associate ...
- PR Newswire•2 months ago
Actinium Pharmaceuticals Announces Participation at BIO-Europe® 24th Annual International Partnering Conference
-Actinium executives will showcase multiple partnering opportunities available via pipeline candidates and technology platform -Assets available for partnering include highly differentiated targeted conditioning ...
- Zacks•2 months ago
Has Actinium Pharmaceuticals (ATNM) Outpaced Other Medical Stocks This Year?
Is (ATNM) Outperforming Other Medical Stocks This Year?
- Zacks•2 months ago
Do Options Traders Know Something About Actinium (ATNM) Stock We Don't?
Investors need to pay close attention to Actinium (ATNM) stock based on the movements in the options market lately.
- PR Newswire•2 months ago
Actinium Pharmaceuticals Announces Webinar Showcasing Actimab-A Post Phase 2 Trial Plans and Actimab-MDS Regulatory Update
NEW YORK, Oct. 22, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that it will host a conference call and webinar to provide key updates on the advancement of its CD33 program on Friday, October 26, 2018 at 11:00 AM ET. Actinium's CD33 program utilizes the Antibody Radio-Conjugate (ARC), lintuzumab-Ac-225 for hematologic indications including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Motorola Solutions, Shire plc, Bitauto, GRIDSUM HOLDING, GW Pharmaceuticals, and Actinium Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•2 months ago
Top Ranked Momentum Stocks to Buy for October 16th
Top Ranked Momentum Stocks to Buy for October 16th
- PR Newswire•2 months ago
Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers
NEW YORK, Oct. 1, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that is has launched its Iomab-ACT program offering its next-generation, chemo-free, targeted lymphodepletion technology to the CAR-T industry. The Iomab-ACT program technology has the potential to be a major improvement over current lymphodepletion regimens due to its targeted mechanism of action that may improve CAR-T cell expansion, reduce CAR-T related toxicities and expand patient access to CAR-T treatment. Actinium recently announced that it has developed an initial estate of six patents related to the Iomab-ACT program supported by its internal research and that it has the support of key physicians from the Froedtert and the Medical College of Wisconsin for the clinical use of Iomab-ACT in conjunction with CAR-T therapy.
- PR Newswire•3 months ago
Actinium Pharmaceuticals to Host Webinar Today Introducing Next Generation Targeted Lymphodepletion Technology for CAR-T
- Conference call and webcast today at 4:15 PM ET - Dr. Nirav Shah, Assistant Professor of Medicine, Division of Hematology and Oncology at Froedtert and the Medical College of Wisconsin will discuss Actinium's ...
- PR Newswire•3 months ago
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced that the Company will participate in the Oppenheimer & Co. Fall Summit Focused on Specialty ...
- Simply Wall St.•3 months ago
Should You Worry About The Actinium Pharmaceuticals Inc’s (NYSEMKT:ATNM) Shareholder Register?
A look at the shareholders of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely,Read More...
- PR Newswire•3 months ago
Actinium Pharmaceuticals to Host Webinar Showcasing New Pipeline Initiative Focused on the CAR-T Space
NEW YORK, Sept. 18, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), announced today that it will unveil a new clinical initiative that expands the Company's pipeline into the CAR-T space. CAR-T is a type of cellular therapy that genetically alters a patient's own T cells to target and kill their cancer cells.
- PR Newswire•3 months ago
Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
NEW YORK, Sept. 6, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) today announced the appointment of Robert N. Daly, M.S., Ph.D., to the position of Vice President, Head of Clinical Operations, effective immediately. In this role, Dr. Daly will oversee all clinical operations, with a focus on executing Actinium's progressing pivotal Phase 3 trial for Iomab-B as a targeted conditioning agent, driving forward the Company's growing CD33 program including its advancement in targeted conditioning, as well as future clinical trial expansion for the entire pipeline.
- PR Newswire•3 months ago
Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions
- Chief Medical Officer, Dr. Mark Berger, to participate in a panel at the B. Riley FBR Healthcare Conference on September 4, 2018 NEW YORK , Sept. 4, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. ...
- PR Newswire•4 months ago
Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
- Conference call to be held at 9:00 AM ET on Wednesday, August 15, 2018 NEW YORK , Aug. 14, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the ...
- ACCESSWIRE•5 months ago
Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
